BridgeMD
New treatment option for Darier Disease
Official title Characterization of the Cytokine Profile and the Microbiome in Darier's Disease
ClinicalTrials.gov ID: NCT06614777
What this study is testing
- What it's testing
- Darier disease is a rare genetic skin disease caused by mutations in the ATP2A2 gene. Clinically, patients present with inflammatory and keratotic papules, sometimes erosive and oozing, predominating in seborrheic areas and folds.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients aged 18 or over,
- MD (clinical diagnosis),
- MD moderate to severe,
- Person affiliated or beneficiary of a social security scheme,
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination...
You likely can't join if
- Other inflammatory dermatological diseases : atopic dermatitis, psoriasis and lichen planus,
- Skin superinfection (clinical diagnosis),
- Treatment with a biotherapy, in progress or in the 12 weeks preceding inclusion,
- Treatment with oral retinoids introduced in the 6 months preceding inclusion,
- Application of tacrolimus to the areas or to more than 30% of the body surface,
- Application of topical corticosteroids to the areas or to more than 30% of the body surface, within 2 weeks preceding inclusion,
See the full eligibility criteria
- Patients aged 18 or over,
- MD (clinical diagnosis),
- MD moderate to severe,
- Person affiliated or beneficiary of a social security scheme,
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
- Other inflammatory dermatological diseases : atopic dermatitis, psoriasis and lichen planus,
- Skin superinfection (clinical diagnosis),
- Treatment with a biotherapy, in progress or in the 12 weeks preceding inclusion,
- Treatment with oral retinoids introduced in the 6 months preceding inclusion,
- Application of tacrolimus to the areas or to more than 30% of the body surface,
- Application of topical corticosteroids to the areas or to more than 30% of the body surface, within 2 weeks preceding inclusion,
- Oral corticosteroid therapy in the 2 weeks preceding inclusion,
- Application of topical retinoids to the areas in the 2 weeks prior to inclusion,
- Oral and/or topical antibiotic therapy in the 2 weeks preceding inclusion,
- Local antiseptic in the 2 weeks preceding inclusion,
- Local keratolytics on areas within 5 days preceding inclusion.
The study team makes the final eligibility decision.
Where it's taking place
- Toulouse, Centre Hospitalier Universitaire de Toulouse, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toulouse, Centre Hospitalier Universitaire de Toulouse, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.